as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹3,272.5
Change
-11.2 (-0.34%)
Open
₹3,294.9
Prev. Close
₹3,283.7
Day High
₹3,311.4
Day Low
₹3,232.0
Volume Analysis
Traded
153,473
Delivered
72,839
Delivery %
47.46%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (24.0%)
- •Strong operating margin (37.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (3)
- •Strong 3-year EPS growth (56.1%)
- •Strong 3-year revenue growth (29.5%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹3,391.34 | ₹3,351.37 | ₹3,311.94 | ₹3,271.97 | ₹3,232.54 | ₹3,192.57 | ₹3,153.14 |
| Fibonacci | ₹3,351.37 | ₹3,321.04 | ₹3,302.3 | ₹3,271.97 | ₹3,241.64 | ₹3,222.9 | ₹3,192.57 |
| Camarilla | ₹3,294.34 | ₹3,287.06 | ₹3,279.78 | ₹3,271.97 | ₹3,265.22 | ₹3,257.94 | ₹3,250.67 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+86.91%
1 Week
-4.47%
1 Month
-0.28%
3 Months
-7.19%
6 Months
+40.32%
1 Year
+140.96%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹444.69
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
21.28%
Net margin 26.47% × asset turnover 0.67x × equity multiplier 1.2x
Company Overview
Sector
Healthcare
Market Cap
₹26,884 Cr
P/E (TTM)
69.6
ROE
24.0%
Book Value
₹202.0
Face Value
₹5.0
Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.
TopFund Analysis
Acutaas Chemicals Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 72/100. The strongest factor is Financial Strength (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (24.0%); strong operating margin (37.0%); promoter holding is falling. Strong 3-year EPS growth (56.1%).
TopFund Score — Fundamentals Quality
72/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Company is expected to give good quarter
- +Company has delivered good profit growth of 45.8% CAGR over last 5 years
- −Stock is trading at 16.3 times its book value
- −Promoter holding has decreased over last 3 years: -6.75%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Board approved acquiring Enchem Ami Organics Pvt Ltd for Rs1 lakh; direct wholly owned subsidiary within one month.
Acutaas Chemicals held its 19th AGM on September 24, 2026, approving final dividend and several resolutions.
Acutaas Chemicals to attend PL Capital Mid & Small Cap Conference on September 28, 2026 in Mumbai.
India granted process patent on September 10, 2026 for 2,4-Dimethylthiophenol; total patents reach 11.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 154 | 172 | 166 | 225 | 177 | 247 | 275 | 308 | 207 | 306 | 393 | 433 | 330 |
| Expenses + | 120 | 148 | 140 | 182 | 147 | 198 | 206 | 224 | 156 | 211 | 243 | 249 | 217 |
| Operating Profit | 34 | 25 | 27 | 43 | 30 | 49 | 69 | 85 | 51 | 95 | 151 | 184 | 113 |
| OPM % | 22.0% | 14.0% | 16.0% | 19.0% | 17.0% | 20.0% | 25.0% | 28.0% | 25.0% | 31.0% | 38.0% | 42.0% | 34.0% |
| Other Income + | 1 | -30 | 3 | 1 | 1 | 8 | 2 | 6 | 16 | 10 | 5 | 11 | 2 |
| Interest | 1 | 1 | 3 | 2 | 4 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 4 | 4 | 4 | 5 | 6 | 7 | 6 | 7 | 8 | 8 | 10 | 10 | 10 |
| Profit before tax | 31 | -10 | 24 | 37 | 20 | 50 | 63 | 83 | 58 | 96 | 145 | 184 | 104 |
| Tax % | 28.0% | 71.0% | 25.0% | 31.0% | 26.0% | 25.0% | 28.0% | 24.0% | 24.0% | 25.0% | 27.0% | 27.0% | 28.0% |
| Net Profit + | 22 | -17 | 18 | 26 | 15 | 38 | 45 | 63 | 44 | 72 | 106 | 134 | 75 |
| EPS in Rs | 3 | -3 | 2 | 3 | 2 | 5 | 5 | 8 | 5 | 9 | 13 | 16 | 9 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 160 | 188 | 239 | 240 | 341 | 520 | 617 | 717 | 1,007 | 1,339 | 1,462 |
| Expenses + | 137 | 157 | 196 | 198 | 260 | 415 | 493 | 589 | 775 | 859 | 919 |
| Operating Profit | 23 | 31 | 42 | 42 | 80 | 105 | 123 | 128 | 232 | 480 | 543 |
| OPM % | 14.0% | 16.0% | 18.0% | 17.0% | 24.0% | 20.0% | 20.0% | 18.0% | 23.0% | 36.0% | 37.0% |
| Other Income + | 0 | 3 | 0 | 2 | 1 | 3 | 4 | -25 | 17 | 42 | 27 |
| Interest | 3 | 3 | 5 | 6 | 6 | 6 | 2 | 6 | 6 | 3 | 4 |
| Depreciation | 1 | 2 | 3 | 4 | 4 | 10 | 12 | 16 | 27 | 36 | 38 |
| Profit before tax | 19 | 28 | 35 | 35 | 72 | 91 | 112 | 82 | 216 | 483 | 529 |
| Tax % | 35.0% | 35.0% | 34.0% | 21.0% | 25.0% | 21.0% | 26.0% | 41.0% | 26.0% | 26.0% | — |
| Net Profit + | 12 | 18 | 23 | 27 | 54 | 72 | 83 | 49 | 160 | 356 | 387 |
| EPS in Rs | 40 | 62 | 11 | 13 | 9 | 10 | 11 | 6 | 19 | 44 | 47 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 15.0% | 13.0% | 26.0% | 8.0% | 6.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 37 | 56 | 72 | 101 | 135 | 486 | 558 | 637 | 1,269 | 1,613 |
| Borrowings + | 27 | 44 | 54 | 59 | 137 | 1 | 4 | 217 | 13 | 36 |
| Other Liabilities + | 43 | 54 | 77 | 61 | 110 | 136 | 169 | 205 | 227 | 295 |
| Total Liabilities | 109 | 155 | 213 | 232 | 413 | 659 | 767 | 1,096 | 1,549 | 1,984 |
| Fixed Assets + | 28 | 32 | 79 | 85 | 186 | 205 | 259 | 427 | 570 | 745 |
| CWIP | 11 | 30 | 2 | 12 | 0 | 3 | 30 | 125 | 130 | 332 |
| Investments | 1 | 3 | 2 | 2 | 1 | 2 | 2 | 0 | 0 | 0 |
| Other Assets + | 68 | 91 | 131 | 133 | 225 | 450 | 477 | 543 | 848 | 907 |
| Total Assets | 109 | 155 | 213 | 232 | 413 | 659 | 767 | 1,096 | 1,549 | 1,984 |
| Equity Capital | 2 | 2 | 10 | 10 | 32 | 36 | 36 | 37 | 41 | 41 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 29 | 8 | 15 | 27 | 28 | -12 | 66 | 125 | 118 | 292 |
| Cash from Investing Activity + | -19 | -25 | -21 | -24 | -101 | -121 | -33 | -365 | -224 | -266 |
| Cash from Financing Activity + | -7 | 15 | 6 | 0 | 72 | 140 | -12 | 239 | 261 | 4 |
| Net Cash Flow | 3 | -2 | 0 | 3 | -1 | 8 | 20 | -1 | 156 | 30 |
| CFO/OP | 153 | 53 | 68 | 85 | 52 | 10 | 73 | 116 | 71 | 84 |
| Free Cash Flow | 10 | -16 | -7 | 6 | -77 | -46 | -31 | -155 | -76 | -36 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 47.97% | 40.85% | 44.31% | 36.28% | 30.24% | 28.27% | 29.22% | 28.0% | 27.89% | 28.96% | 28.24% | 26.16% |
| Promoters | 38.93% | 39.91% | 39.91% | 35.98% | 35.97% | 35.96% | 35.96% | 32.66% | 32.66% | 32.66% | 32.66% | 32.66% |
| Government | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| FII | 7.15% | 11.66% | 8.98% | 12.93% | 13.87% | 15.52% | 16.48% | 16.94% | 16.84% | 16.67% | 19.48% | 21.61% |
| DII | 5.95% | 7.58% | 6.8% | 14.81% | 19.93% | 20.23% | 18.31% | 22.38% | 22.59% | 21.7% | 19.6% | 19.55% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Acutaas Chemicals Limited (this stock) | 26,884 | 69.6 | 16.26 | 24.0% |
| Rubicon Research Limited | 27,748 | 96.3 | 21.46 | 27.0% |
| Piramal Pharma Limited | 28,000 | — | 3.42 | -3.83% |
| Neuland Lab Ltd. | 28,085 | 56.4 | 14.98 | 21.2% |
| Granules India Limited | 23,248 | 35.8 | 4.16 | 13.8% |
| Dr. Lal Path Labs Ltd. | 32,299 | 57.4 | 12.83 | 22.3% |
| Caplin Point Lab Ltd. | 21,173 | 31.9 | 6.29 | 20.9% |
Which Mutual Funds Hold Acutaas Chemicals Limited?
Frequently Asked Questions about Acutaas Chemicals Limited
Acutaas Chemicals Limited (ACUTAAS) closed at ₹3,272.5 on NSE on 25 September 2026, down 11.2 (0.34%) from the previous close.
Acutaas Chemicals Limited trades on the NSE (National Stock Exchange of India) under the symbol ACUTAAS.
Acutaas Chemicals Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 69.6.
Acutaas Chemicals Limited has a dividend yield of 0.08%.
Acutaas Chemicals Limited's 52-week high is ₹3,740.0 and its 52-week low is ₹1,290.0.
Acutaas Chemicals Limited has a market capitalisation of ₹26,884 crore.
Acutaas Chemicals Limited has a TopFund Quality Score of 72/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Acutaas Chemicals Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.